Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
NEW YORK, July 1, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) as well as the tumor bulk, announced today that it has been added to the Russell 3000® Index, effective prior to the market open on Monday, July 1, 2013.
Help employers find you! Check out all the jobs and post your resume.
